[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover bioequivalence pre-trial of vonoprazan fumarate tablets (20 mg) in healthy Chinese subjects under fasting administration conditions.

主要研究目的：按有关生物等效性预试验的规定，选择Takeda Pharmaceutical Company Limited为持证商的富马酸伏诺拉生片（商品名：沃克®，规格：20mg）为参比制剂，对海南亚洲制药股份有限公司生产并提供的受试制剂富马酸伏诺拉生片（规格：20mg）进行空腹条件下给药的人体生物等效性预试验，比较两种制剂在中国健康试验参与者体内的药代动力学行为，评估两种制剂在空腹给药条件下生物等效性的可能性，为正式试验设计提供参考依据。次要研究目的：观察健康受试者口服受试制剂富马酸伏诺拉生片（规格：20mg）和参比制剂富马酸伏诺拉生片（商品名：沃克®，规格：20mg）的安全性。

[Translation]

Primary Objective: In accordance with relevant regulations for bioequivalence pre-tests, vonoprazan fumarate tablets (trade name: Walker®, strength: 20mg), manufactured by Takeda Pharmaceutical Company Limited, was selected as the reference formulation. A human bioequivalence pre-test was conducted on the test formulation, vonoprazan fumarate tablets (strength: 20mg), manufactured and supplied by Hainan Asia Pharmaceutical Co., Ltd., under fasting conditions. The pharmacokinetic behavior of the two formulations in healthy Chinese participants was compared to assess the likelihood of bioequivalence under fasting conditions, providing a reference for the design of the formal trial. Secondary Objective: To observe the safety of oral administration of the test formulation, vonoprazan fumarate tablets (strength: 20mg), and the reference formulation, vonoprazan fumarate tablets (trade name: Walker®, strength: 20mg), in healthy subjects.

Start Date16 Mar 2026

Sponsor / Collaborator

Hainan Asia Pharmaceutical Co., Ltd.

NCT07439445

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Simplified Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line Helicobacter Pylori Eradication

To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.

Start Date24 Feb 2026

Sponsor / Collaborator

Peking University First Hospital

NCT07293910

/ RecruitingPhase 2IIT

Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity. Its clinical significance is profound: it is classified as a Group 1 carcinogen by the World Health Organization and is a primary cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. The current first-line treatment, a PPI-based triple therapy (PPI + clarithromycin + amoxicillin), is experiencing a decline in efficacy (cure rates of 50-70%) due to widespread antibiotic resistance and compliance issues. To overcome this, newer agents like Vonoprazan Fumarate, a Potassium-Competitive Acid Blocker (P-CAB), are being adopted. Vonoprazan works by reversibly inhibiting the H+, K+ ATPase pump achieving stronger and longer-lasting acid suppression than PPIs because it does not require acid activation and is more stable in an acidic environment. In addition to pharmacological treatment, adjunctive therapies show promise. Vitamin D, acting through Vitamin D Receptor (VDR), assists in eradication by upregulating antimicrobial proteins like beta-defensin and cathelicidin, and its metabolite can cause bacterial cell lysis. Probiotics (primarily Lactobacillus and Bifidobacterium strains) enhance eradication rates by restricting bacterial growth, inhibiting adhesion, and exerting an anti-inflammatory effect through decreased interleukin-8 production. Finally, helicobacter pylori infection is marked by significant inflammation and oxidative stress. The bacterial protein TIP alpha induces high levels of the pro-inflammatory cytokine TNF alpha. Furthermore, the infection increases free radical production, leading to oxidative stress reflected by high levels of malondialdehyde. Systemic inflammation is also evident as helicobacter pylori infection is associated with significantly elevated serum C-reactive protein levels, which decrease upon successful eradication.
Aim of the work:
This study aims at evaluating the safety and efficacy of Vonoprazan vs Proton Pump Inhibitor with Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection.

Start Date15 Feb 2026

Sponsor / Collaborator

Tanta University

100 Clinical Results associated with Vonoprazan Fumarate

100 Translational Medicine associated with Vonoprazan Fumarate

100 Patents (Medical) associated with Vonoprazan Fumarate

835

Literatures (Medical) associated with Vonoprazan Fumarate

01 May 2026·LIFE SCIENCES

Vonoprazan mitigates diethyl nitrosamine-induced acute liver injury in mice via modulating p-AMPK/ SIRT1/ PGC-1α and Keap1/Nrf2/HO-1 pathways

Article

Author: Al-Rasheedi, Zaid F ; El-Kashef, Dalia H ; Nour, Omnia A

BACKGROUND:

Vonoprazan (VON), a potassium-competitive acid blocker, is used in the treatment of acid-related disorders including GERD, gastritis, and esophagitis besides H. pylori infection.

AIM:

This study was carried out to elucidate the hepatoprotective effect of VON against diethylnitrosamine (DN)-induced acute liver injury (ALI) in mice.

METHOD:

Thirty-six male mice were randomly alienated into six groups, including control group, VON20 group, DN-induced ALI group, VON5 + DN group, VON10 + DN group and VON20 + DN group. ALI was induced in mice using DN (150 mg/kg, i.p.). VON was orally administered at three doses (5, 10 and 20 mg/kg) for 7 days before DN injection, and DN was injected on day 7.

RESULTS:

In comparison to DN group, VON exerted hepatoprotective effect, evidenced by significant decrease in serum levels of ALT, AST, GGT and LDH. Additionally, VON administration restored oxidant/anti-oxidant balance, as presented by significant decrease in hepatic levels of MDA in addition to profound increase in hepatic level of GSH and TAC. Furthermore, VON administration attenuated DN-induced reduction in hepatic levels of p-AMPK, SIRT1, PGC-1α, Nrf2 and HO-1. VON also induced significant reduction in hepatic levels of Keap1, NF-κB and TNF-α when compared to DN. Histopathologically, VON mitigated DN-induced histopathological irregularities in hepatic tissues.

CONCLUSION:

VON suggests hepatoprotective potential, in a dose dependent manner, possibly due to their antioxidant and anti-inflammatory properties.

01 Apr 2026·DEN open

A Case of Gastric Neuroendocrine Tumor With a Raspberry‐Like Appearance on the Background of Acid‐Suppressive Therapy‐Related Gastropathy

Article

Author: Arakawa, Takeo ; Noma, Eriko ; Funabiki, Toshihiro ; Goto, Osamu ; Moriguchi, Yoshiaki ; Iseki, Mari ; Oka, Yasuhiro ; Nakahodo, Jun ; Iizuka, Toshiro ; Horiguchi, Shin‐ichiro

ABSTRACT:

We report the case of a 52‐year old man who was referred to our institution after a routine health check identified an asymptomatic gastric polyp. The medical history of the patient included reflux esophagitis, for which he had been treated with vonoprazan 10 mg daily for 6 years after initially receiving proton pump inhibitors. Endoscopy revealed a 4‐mm, hemispherical, uniformly reddish Yamada type II lesion on the anterior wall of the gastric body, arising from nonatrophic mucosa with multiple small hyperplastic polyps. Magnifying narrow‐band imaging revealed a regular microvascular and microsurface pattern, producing a raspberry‐like appearance. Histological examination of the biopsy specimen revealed a grade 1 neuroendocrine tumor. Contrast‐enhanced computed tomography revealed no evidence of metastatic lesions. En bloc resection was successfully performed using endoscopic submucosal dissection. Pathological examination confirmed a 5‐mm grade 1 neuroendocrine tumor with negative margins and no vascular invasion. Gastric neuroendocrine tumors with raspberry‐like morphology are rare. This case underscores the importance of considering gastric neuroendocrine tumors in the differential diagnosis of raspberry‐like gastric lesions, particularly in patients with potent acid‐suppressive therapy–related gastropathy.Trial Registration : N/A.

01 Mar 2026·HELICOBACTER

Efficacy and Safety of Vonoprazan‐Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial

Article

Author: Li, Ji ; Zhang, Jin‐Yan ; Huang, Yu‐Lin ; Lei, Xiao‐Yi ; Xu, Gui‐Hua ; Huang, Wei‐Feng ; Xu, Dong

ABSTRACT:

Background:

Vonoprazan (VPZ), a potassium‐competitive acid blocker, has shown promising efficacy in Helicobacter pylori ( H. pylori ) eradication. However, direct comparisons of VPZ‐based dual therapy (V‐DT), triple therapy (V‐TT), and bismuth quadruple therapy (V‐BQT) remain limited. This study aimed to evaluate and compare the efficacy, safety, and compliance of these three regimens as first‐line treatments for H. pylori infection.

Methods:

375 adults were randomized (1:1:1) to receive V‐DT (VPZ 20 mg bid + amoxicillin 1 g tid for 10 days), V‐TT (VPZ 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid for 14 days), or V‐BQT (VPZ 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid + bismuth 240 mg bid for 10 days). The primary outcome was H. pylori eradication rate by intention‐to‐treat (ITT), modified ITT (mITT), and per‐protocol (PP) analyses. Secondary outcomes included adverse events and compliance.

Results:

Eradication rates were 92.0% (95% confidence interval [CI]: 85.8%–96.1%), 89.6% (95% CI: 82.9%–94.3%), and 88.8% (95% CI: 81.9%–93.7%) in ITT; 94.3% (95% CI: 88.5%–97.7%), 94.9% (95% CI: 89.3%–98.1%), and 94.1% (95% CI: 88.2%–97.6%) in mITT; and 94.2% (95% CI: 88.4%–97.6%), 95.6% (95% CI: 90.0%–98.5%), and 94.8% (95% CI: 89.0%–98.1%) in PP analyses for V‐DT, V‐TT, and V‐BQT, respectively. The efficacy of V‐DT and V‐TT was noninferior to that of V‐BQT. Adverse events were significantly lower with V‐DT (6.4%) than with V‐TT (36.0%) and V‐BQT (49.6%) ( p < 0.001). Compliance exceeded 93% in all groups, with no significant differences ( p = 0.250).

Conclusions:

All three regimens achieved high eradication rates, with V‐DT and V‐TT being statistically noninferior to V‐BQT. The 10‐day V‐DT regimen achieved eradication rates comparable to V‐BQT with substantially fewer adverse events and reduced antibiotic use, supporting its potential as a simplified first‐line option for H. pylori eradication.

Trial Registration:

Chinese Clinical Trial Registration Number: ChiCTR2300072857

130

News (Medical) associated with Vonoprazan Fumarate

06 Apr 2026

·www.globenewswire.com

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NYDate: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDTManagement to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

License out/in

06 Apr 2026

·www.biospace.com

Phathom Pharmaceuticals to Participate in Upcoming April 2026 Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NY Date: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 15, 2026 Fireside Chat: 1:30 pm EDT Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at . Recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA ® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at and follow on LinkedIn and X . MEDIA CONTACT Nick Benedetto 1-877-742-8466 media@phathompharma.com INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

License out/inDrug Approval

08 Jan 2026

·www.biospace.com

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock. The shares of common stock are being sold to the public at a price of $16.00 per share and the pre-funded warrants are being sold at a price of $15.999 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130 million. In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 1,218,761 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 9, 2026, subject to satisfaction of customary closing conditions. Phathom intends to use the net proceeds from the offering for general corporate purposes, including for working capital and commercialization and research and development expenses. Guggenheim Securities and Cantor are acting as joint bookrunning managers for the offering. Raymond James, Needham & Company, H.C. Wainwright & Co. and Craig-Hallum are acting as co-managers for the offering. The securities described above are being offered by Phathom pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (SEC) on January 7, 2026 and became effective automatically upon filing. The proposed offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus and accompanying prospectus were filed with the SEC and is available on the website of the SEC at When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the website of the SEC at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Phathom Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA ® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. Forward-Looking Statements Phathom cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements relating to the satisfaction of customary closing conditions related to the offering, the expected closing of the offering and the anticipated gross proceeds from the offering and Phathom’s intended use of the net proceeds therefrom. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in Phathom’s business described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. CONTACTS Media Contact: Nick Benedetto 1-877-742-8466 media@phathompharma.com Investor Contact: Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

Drug ApprovalLicense out/in

100 Deals associated with Vonoprazan Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D10466	Vonoprazan Fumarate	A02BC08	DB11739

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-erosive gastro-esophageal reflux disease	United States	Phathom Pharmaceuticals, Inc.	17 Jul 2024
Erosive esophagitis	United States	Phathom Pharmaceuticals, Inc.	01 Nov 2023
Heartburn	United States	Phathom Pharmaceuticals, Inc.	01 Nov 2023
Erosive gastro-esophageal reflux disease	South Korea	Takeda Pharmaceuticals Korea Co., Ltd.	29 Mar 2019
Duodenal Ulcer	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014
Esophagitis, Peptic	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014
Helicobacter pylori infection	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014
Stomach Ulcer	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peptic Ulcer Hemorrhage	NDA/BLA	China	YiChang HEC ChangJiang Pharmaceutical Co., Ltd.	08 Apr 2026
Non-erosive reflux disease	Phase 3	United States	Phathom Pharmaceuticals, Inc.	17 Jan 2022
Eosinophilic Esophagitis	Phase 2	United States	Phathom Pharmaceuticals, Inc.	30 Oct 2025
Gastroesophageal Reflux	Phase 2	Belgium	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Bulgaria	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Czechia	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Estonia	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Poland	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	United Kingdom	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Dyspepsia	Phase 1	China	Zhejiang Jianfeng Pharmaceutical Co., Ltd.	17 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06831344 (CTgov)	Phase 1	-	25	Vonoprazan (Treatment A: Vonoprazan 10 mg)	okejeuqeze(oeypndmlye) = bdoraejegi mhxhphvlsv (tpimpmfrck, 47.8) View more	-	19 Dec 2025
				Vonoprazan (Treatment B: Vonoprazan 10 mg)	okejeuqeze(oeypndmlye) = iynkugopyy mhxhphvlsv (tpimpmfrck, 41.4) View more
NCT04198363 (Pubmed \| Chin Med J (Engl))	Phase 3	Helicobacter pylori infection	510	Vonoprazan-based quadruple therapy	fzudvbtgjs(khamzdnpht) = fflwodaxok lsxupcflcj (sveicvpvge )	Positive	20 Nov 2025
				Esomeprazole-based quadruple therapy	fzudvbtgjs(khamzdnpht) = uveyrsvpem lsxupcflcj (sveicvpvge )
NCT05195528 (Pubmed \| Am J Gastroenterol)	Phase 3	Non-erosive reflux disease	772	Placebo	gnukwccemx(wbjirwnmha) = zrsjtpsbrm ujefootqhb (sewfyfvwyp )	Positive	13 Oct 2025
				Vonoprazan 10 mg	gnukwccemx(wbjirwnmha) = ukhujwqytj ujefootqhb (sewfyfvwyp )
NCT06162949 (VONTAPE, Pubmed \| Helicobacter)	Phase 4	Helicobacter pylori infection	242	Vonoprazan-Based Triple Therapy	kdfjejwqbx(gytmzkxffk) = thjeanvqsn kicoautytt (bolklooydb ) View more	Positive	01 Sep 2025
				Esomeprazole-Based Triple Therapy	kdfjejwqbx(gytmzkxffk) = vybutecdfq kicoautytt (bolklooydb ) View more
NCT06811207 (Pubmed \| Ther Adv Gastroenterol)	Phase 4	Helicobacter pylori infection First line	121	vonoprazan+amoxicillin	biqlhukwlx(czgtoryiiw) = vdqprnepmu jomgbnxutd (spqbforrkz ) View more	Similar	01 Sep 2025
				esomeprazole+amoxicillin	biqlhukwlx(czgtoryiiw) = kyjdlliwhg jomgbnxutd (spqbforrkz ) View more
NCT06168084 (not provided, Pubmed \| United European Gastroenterol J)	Phase 4	Helicobacter pylori infection	688	Vonoprazan and High-Dose Amoxicillin (VHA) dual therapy	yngoumyspb(emghqqpaii) = The overall AE incidence in the VHA group was significantly lower compared with that in the TFEB group (13.4% vs.. 28.5%, p < 0.001) tqhagihpqp (bteynqmdpl )	Positive	21 Jun 2025
				Tetracycline- and Furazolidone-based Bismuth-Containing Quadruple Therapy (TFEB)
NCT05191888 (Pubmed \| Am J Gastroenterol)	Phase 3	Helicobacter pylori infection First line	906	Vonoprazan high-dose dual therapy	treipvdkic(pqvsuznzei) = hfdtpxzclb rvuokvocqm (fulbovjdsc ) View more	Positive	16 Jun 2025
				Vonoprazan triple therapy	treipvdkic(pqvsuznzei) = frteglfteq rvuokvocqm (fulbovjdsc ) View more
NCT05649540 (Pubmed \| Helicobacter)	Phase 4	Helicobacter pylori infection	900	High-dose amoxicillin (HVA)	ygxxcxyxzf(hvkeakelli) = plspitzcfy vapusjabtu (uvmqtxxkwk )	Positive	01 May 2025
				Medium-dose amoxicillin (MVA)	ygxxcxyxzf(hvkeakelli) = ctqgimppol vapusjabtu (uvmqtxxkwk )
NCT06391177 (CTgov)	Phase 1	Erosive esophagitis \| Helicobacter pylori infection \| Gastroesophageal Reflux ... View more	15	Vonoprazan (Vonoprazan 20 mg QD)	ofyuafeqkk(zptianrzkn) = hwpjmajwkc ghsrcqemxs (imvhxqaepm, 61.3) View more	-	25 Mar 2025
				Vonoprazan (Vonoprazan 20 mg BID)	ofyuafeqkk(zptianrzkn) = xdrbxpkecp ghsrcqemxs (imvhxqaepm, 107) View more
NCT05469685 (Pubmed \| Front Pharmacol)	Phase 4	Helicobacter pylori infection	914	10-day vonoprazan-amoxicillin (VA) therapy	lrtqstcjuu(vkmpoogmqm) = idslsnakez kubgdcgxae (onnemmkvty ) View more	Positive	24 Mar 2025
				14-day vonoprazan-amoxicillin (VA) therapy	lrtqstcjuu(vkmpoogmqm) = kfucgfcryx kubgdcgxae (onnemmkvty ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis